This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Drug Therapy, Other  • Randomized Controlled Trial  • Psychopharmacology  • Drug Therapy  • Schizophrenia  • Alert me on articles by topic

Rajiv Tandon, MD; William T. Carpenter, MD; John M. Davis, MD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

We sought to understand how findings of the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS band 1)¹ and their comparison with those from phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study in schizophrenia^2-3 clarify issues raised in our 2005 American Psychiatric Association annual meeting debate "Second-Generation Antipsychotics (SGAs) Are Uniformly Superior in Efficacy and Safety to First-Generation Antipsychotics (FGAs)."⁴ Applying the primary effectiveness metric used in CATIE to CUtLASS band 1 findings, we noted that in contrast to 60 of 118 patients (51%) assigned to receive an FGA who continually took an FGA through the 1-year study, 70 of 109 patients (64%) assigned to receive an SGA did so (²₁ = 4.14; P < .05). In CUtLASS band 1, SGAs were found to be more effective than FGAs in terms of all-cause discontinuation. . . . [Full Text of this Article]

AUTHOR INFORMATION

RELATED ARTICLES

Comparative Effectiveness of Antipsychotic Drugs: A Commentary on Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)
Jeffrey A. Lieberman
Arch Gen Psychiatry. 2006;63(10):1069-1072.
EXTRACT | FULL TEXT  

Randomized Controlled Trial of the Effect on Quality of Life of Second- vs First-Generation Antipsychotic Drugs in Schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)
Peter B. Jones, Thomas R. E. Barnes, Linda Davies, Graham Dunn, Helen Lloyd, Karen P. Hayhurst, Robin M. Murray, Alison Markwick, and Shôn W. Lewis
Arch Gen Psychiatry. 2006;63(10):1079-1087.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Impact of the CATIE Findings on State Mental Health Policy
Parks et al.
Psychiatr. Serv. 2008;59:534-536.
ABSTRACT | FULL TEXT  

Principles of Antipsychotic Prescribing for Policy Makers, Circa 2008. Translating Knowledge to Promote Individualized Treatment
Parks et al.
Schizophr Bull 2008;0:sbn019v1-sbn019.
ABSTRACT | FULL TEXT